May is ankylosing spondylitis month and to celebrate, we would like to share this question and answer session Arthritis Consumer Experts did with Michael Mallinson, President of the Canadian Spondylitis Association.
Q: Hi, Michael. Can you tell us about your organization?
A: The Canadian Spondylitis Association is a nonprofit national patient association formed in April 2006 to support and to advocate for those suffering from ankylosing spondylitis and associated spondyloarthritis diseases including psoriatic arthritis, enteropathic arthritis and reactive arthritis. Our goal is to be the leader in Canada providing support, education and advocacy for the spondyloarthritis patient community
Q: What are some misconceptions about ankylosing spondylitis?
A: Most people are unaware that AS strikes young people. The typical age of onset is between 17 and 35. Although people are aware that arthritis is a women’s disease, they are surprised when they found out AS has a significantly higher prevalence among men.
Health Canada has issued a warning about ingredients in PureCare Herbal Cream
PureCare Herbal Cream, advertised as a natural treatment for eczema and psoriasis in children and babies, may pose serious health risks.
Health Canada testing confirmed the presence of a prescription steroid (clobetasol propionate) and another ingredient (phenoxylethanol) not declared on the product label. These ingredients may cause health effects ranging from skin irritation and dehydration to increased blood pressure. Continue reading
Now that psoriatic arthritis (PsA) is viewed as its own disease entity and no longer as a relative of rheumatoid arthritis, trends in PsA care have started to change. Methotrexate has become a first-line treatment for PsA patients, and at the American College of Rheumatology (ACR) annual meeting this week, the spotlight was on new disease modifying antirheumatic agents (DMARDs) for PsA. According to Dr. Laura Coates, National Institute for Health Research Clinical Lecturer in Rheumatology at the University of Leeds, United Kingdom: “It is quite an exciting time for psoriatic arthritis because we are getting new drugs that are specific for PsA. A lot of the newer drugs focus on the Il-17 pathway, which is a different part of the patient’s immune system (than what previous medications targeted) and which seems to be particularly important for psoriatic arthritis, psoriasis, and spondylitis arthritis.”
Professional golfer Phil Mickelson was diagnosed with psoriatic arthritis in 2010. At first, his joints ached and then one day, he could barely get out of bed due to agonizing pain. While he waited for test results from his rheumatologist, he played in the 2010 U.S. Open and landed a fourth place finish.
If untreated, psoriatic arthritis can affect Mickelson’s golf game. The swelling of the hands and toes can affect his ability to stabilize his swing and stance. Swelling in the hands can also affect how he grips his club. With the help of medications, Mickelson is back in the game. Off the golf course, he is a vocal advocate of raising awareness for arthritis. Continue reading
Correction for apremilast (Otezla®) listing in the Ontario drug formulary
A reference in the July 12, 2016 online publication of JointHealth™ insight referred incorrectly to the listing of apremilast (Otezla®) for the treatment of psoriatic arthritis in the Ontario drug formulary as “declined.” The medication should be listed as “under review” as it is still under consideration for reimbursement.
Click here to see the updated Report Card.
We want to hear from you. If you have been affected by the delayed review of apremilast (Otezla®), please contact us at firstname.lastname@example.org.
In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).
The following medication has been listed for reimbursement on the provincial drug formulary: Continue reading